Of note, another two clinical trials (NCT04114136, NCT03311308) have been conducted to forwardly verify the therapeutic value of the combined complication of both metformin and anti-PD-1 antibody in melanoma and other types of solid tumors. This evidence concerns the gene PDCD1 and melanoma.